DEERFIELD, Ill.--(BUSINESS WIRE)--
Baxter International Inc. (NYSE: BAX), a global innovator in renal care
for more than 60 years, today announced its recently launched
SHARESOURCE remote patient management system has helped healthcare
providers manage more than 150,000 peritoneal dialysis (PD) treatments
performed in patients' homes. The treatment milestone represents the
large-scale application of the first and only two-way, telehealth
platform to support home dialysis therapy.
"From urban to rural locations around the world, healthcare providers
are quickly adopting Baxter's SHARESOURCE technology with either AMIA or
HOMECHOICE CLARIA automated peritoneal dialysis systems," says Giuseppe
Accogli, corporate vice president and president, Baxter Renal. "Baxter's
new APD systems with SHARESOURCE are designed to help more patients gain
access to home dialysis therapy and provide their physicians with
greater ability to remotely manage their care."
Baxter's SHARESOURCE remote patient management system is a two-way,
cloud-based technology platform that allows designated healthcare
providers to securely view recently completed dialysis-related treatment
data that is automatically collected after each PD session. Healthcare
providers can act on this information by securely and remotely adjusting
their patients' home device settings without requiring patients to
travel to the clinic. The SHARESOURCE system also provides a patient's
healthcare team better visibility to their missed treatments. The
healthcare provider can then proactively follow up with their patient to
address any potential issues.
The recently launched telehealth platform is offered with Baxter's AMIA
and HOMECHOICE CLARIA automated peritoneal dialysis (APD) systems, where
those systems are cleared for use worldwide.
In the United States, SHARESOURCE is available on Baxter's AMIA APD
system. The AMIA system has advanced features such as animated graphics
and automated step-by-step instructions with voice guidance. The system
was designed to provide a user-friendly experience that helps guide
patients through their home therapy. AMIA also is up to 40 percent
smaller and 30 percent lighter than other cyclers on the market, and
features a folding design when the touch screen is not in use.1, 2
The compact design means AMIA can be packed in a car or taken onboard an
airplane, enabling patients to conduct therapy when traveling for work
or leisure.
HOMECHOICE CLARIA with SHARESOURCE is available in select European and
Asian countries and has recently launched in Latin America. The system
features a large, two-line display screen for better visibility, and a
universal interface that is available in 41 languages.
PD works by cleaning the blood of toxins and removing extra fluid
through the body's peritoneal cavity. The ability to choose when and
where therapy is done means APD may offer lifestyle benefits, such as
being able to work during normal business hours. One study concluded
patients who maintained the same level of employment during the six
months prior to kidney failure, were significantly more likely to choose
PD as their initial therapy.3
For prescription only. For safe and proper use of the devices
mentioned herein, refer to the complete instructions in the Operator's
Manual.
About Baxter International Inc.
Baxter provides a broad portfolio of essential renal and hospital
products, including home, acute and in-center dialysis; sterile IV
solutions; infusion systems and devices; parenteral nutrition;
biosurgery products and anesthetics; and pharmacy automation, software
and services. The company's global footprint and the critical nature of
its products and services play a key role in expanding access to
healthcare in emerging and developed countries. Baxter's employees
worldwide are building upon the company's rich heritage of medical
breakthroughs to advance the next generation of healthcare innovations
that enable patient care.
This release includes forward-looking statements concerning Baxter's
AMIA and HOMECHOICE CLARIA APD systems and the SHARESOURCE connectivity
platform, including anticipated benefits associated with its use. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements: satisfaction of
regulatory and other requirements; actions of regulatory bodies and
other governmental authorities; product quality, manufacturing or supply
issues; patient safety issues; changes in law and regulations; breaches
or failures of the company's information technology systems; and other
risks identified in Baxter's most recent filing on Form 10-K and other
SEC filings, all of which are available on Baxter's website. Baxter does
not undertake to update its forward-looking statements.
Baxter, Amia, HomeChoice Claria and Sharesource are registered
trademarks of Baxter International Inc.
1 Amia Automated PD System Patient Guide. Baxter Healthcare
Corporation. Deerfield, IL.
2 HomeChoice and HomeChoice
PRO APD Systems Patient At-Home Guide. Baxter Healthcare Corporation.
Deerfield, IL.
3 Muehrer, Rebecca J., et al. Factors
Affecting Employment at Initiation of Dialysis. CJASN. March
2011. vol. 6 no. 3 489-496
View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005310/en/
